Form 4 for RARE Ultragenyx Pharmaceutical Inc.
Accepted 2025-05-19 00:00:00 ET · period of report 2025-05-15 · accession 0000950170-25-074669 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-05-19 | 2025-05-15 | RARE | SULIMAN SHEHNAAZ | Dir | A - Grant | $0.00 | +5,740 | 25.9K | +28% | $0 |
| D | 2025-05-19 | 2025-05-15 | RARE | SULIMAN SHEHNAAZ | Dir | A - Grant | $0.00 | +10.8K | 10.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-15 | A | A | 5,740 | $0.00 | 25,940 | D | — | — | (F1) Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026. |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-05-15 | A | A | 10,787 | $0.00 | 10,787 | D | $34.84 · — to 2035-05-15 | 10,787 Common Stock | (F2) The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026. |